Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease

Shaomin Li*, Ming Jin, Lei Liu, Yifan Dang, Beth L. Ostaszewski and Dennis J. Selkoe

Abstract
Pathologic, biochemical and genetic evidence indicates that accumulation and aggregation of amyloid β-proteins (Aβ) is a critical factor in the pathogenesis of Alzheimer’s disease (AD). Several therapeutic interventions attempting to lower Aβ have failed to ameliorate cognitive decline in patients with clinical AD significantly, but most such approaches target only one or two facets of Aβ production/clearance/toxicity and do not consider the heterogeneity of human Aβ species. As synaptic dysfunction may be among the earliest deficits in AD, we used hippocampal long-term potentiation (LTP) as a sensitive indicator of the early neurotoxic effects of Aβ species. Here we confirmed prior findings that soluble Aβ oligomers, much more than fibrillar amyloid plaque cores or Aβ monomers, disrupt synaptic function. Interestingly, not all (84%) human AD brain extracts are able to inhibit LTP and the degree of LTP impairment by AD brain extracts does not correlate with Aβ levels detected by standard ELISAs. Bioactive AD brain extracts also induce neurotoxicity in iPSC-derived human neurons. Shorter forms of Aβ (including Aβ1-37, Aβ1-38, Aβ1-39), pre-Aβ APP fragments (−30 to −1) and N-terminally extended Aβs (−30 to +40) each showed much less synaptotoxicity than longer Aβs (Aβ1-42 - Aβ1-46). We found that antibodies which target the N-terminus, not the C-terminus, efficiently rescued Aβ oligomer-impaired LTP and oligomer-facilitated LTD. Our data suggest that preventing soluble Aβ oligomer formation and targeting their N-terminal residues with antibodies could be an attractive combined therapeutic approach.

Keywords: Alzheimer’s disease, Amyloid-beta protein, Synaptic plasticity, Long-term potentiation, Oligomers

Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible cognitive decline. The pathological hallmarks of AD are the aberrant deposition of extracellular senile plaques comprised of amyloid-beta (Aβ) peptides and intracellular neurofibrillary tangles composed of altered forms of the tau protein. A growing body of evidence from genetic, in vivo imaging and biochemical studies has demonstrated that accumulation of oligomeric, diffusible assemblies of Aβ peptides, rather than mature amyloid fibrils, is the earliest pathogenic event in the ontogeny of AD [7, 43, 62, 70, 71].

Aβ peptides are generated throughout life from the amyloid precursor protein (APP) via a sequential, two-step proteolytic cleavage: first by β-site APP-cleaving enzyme 1 (BACE1), also called β-secretase, and then by the presenilin/γ-secretase complex [36, 49, 80]. Transgenic APP mutant mouse models showed that increasing β- or γ-secretase activity promotes the production of pathogenic Aβ and induces AD-like pathology, while decreasing their activities by inhibitors can reduce brain Aβ levels and ameliorate AD neuropathology and resultant behavioral deficits [9, 13]. Experimentally, the deposition of Aβ can be accelerated in the brains of APP-transgenic mice after intracerebral or intraperitoneal injection with Aβ aggregate-containing brain homogenate. This effect can be
Materials and methods
Mice
The Harvard Medical School and Brigham Women’s hospital Standard Committee on Animals approved all experiments involving mice used for electrophysiology and biochemical assays. All mice (male and female) contained a mixed background of C57Bl/6 and 129. Animals were housed in a temperature-controlled room on a 12-h light/12-h dark cycle and had ad libitum access to food and water.
Two-tailed Student’s t-test and one-way analysis of variance (ANOVA) were used to determine statistical significance.

**Human brain homogenate preparation**

Homogenates of human brains were prepared as described elsewhere [64, 81]. Frozen brain tissue collected at Massachusetts Alzheimer’s Disease Research Center (MADRC Neuropathology Core, Harvard, MA, USA) and Brigham and Women’s Hospital under institutional review board-approved protocols. Frozen samples of temporal or frontal cortex (1 g) were allowed to thaw on ice, chopped into small pieces with a razor blade, and then homogenized with 25 strokes of a Dounce homogenizer (Fisher, Ottawa, ON, Canada) in 4 ml ice-cold 20 mM Tris–HCl, pH 7.4, containing 150 mM NaCl (Tris-buffered saline (TBS)) and protease inhibitors. Water-soluble Aβ was separated from membrane-bound and plaque Aβ by centrifugation at 175,000×g and 4 °C in a TLA 100 rotor (Beckman Coulter, Fullerton, CA, USA) for 30 min, and the supernatant (referred to as TBS extract) aliquoted and stored at –80 °C. The ethical body approving this study was the Partners Institutional Review Board of the Partners Human Research Committee.

**Production of induced neurons (iNs) from human induced pluripotent cells (iPSCs)**

The YZ1 iPSC line was obtained from UCONN stem cell core [84] and used to prepare neurogenin 2 (Ngn2)-induced human neurons [86]. iPSCs were maintained in media containing DMEM/F12, Knockout Serum Replacement, penicillin/streptomycin/glutamine, MEM-NEAA, and 2-mercaptoethanol (all from Invitrogen, Carlsbad, CA) with addition of 10 µg/mL bFGF (Millipore, Billerica, MA) directly prior to media application. Neuronal differentiation was performed via doxycycline induced Neurogenin 2 system [86]. iPSCs were plated at a density of 95,000 cells/cm² for viral infection. Lentiviruses were obtained from Alstem with “ultrapure titres” and used at the following concentrations: pTet-O-NGN2-puro: 0.1 µl/50,000 cells; Tet-O-FUW-eGFP: 0.05 µl/50,000 cells; Fudelta GW-rTAC: 0.11 µl/50,000 cells. To induce Neurogenin 2 expression doxycycline is added on iN day 21. Whole image sets were analyzed using Incucyte Zoom live-cell imaging instrument (Essen Bioscience, Ann Arbor, MI). Four fields per well of a 96 well plate were imaged every 2 h for a total of 6 h. This analysis was used to define neurite length and branch points prior to addition of brain extracts. Buffer exchanged brain extracts were diluted 1:2 with culture medium. Half of the medium on iNs was removed (~100 µl) and replaced with 100 µl of 1:2 diluted buffer-exchanged extract – yielding a 1:4 diluted extract on iNs. Similarly, treatments using 1:8 and 1:16 diluted extracts were done in a similar manner. For long-term, continuous imaging, images of four fields per well were acquired every 2 h for 3 days (starting at iN day 21). Whole image sets were analyzed using Incucyte Zoom 2016A Software. The analysis job Neural Track was used to automatically define neurite processes and cell bodies based on phase contrast images. Typical settings were: Segmentation Mode - Brightness; Segmentation Adjustment - 1.2; Cell body cluster filter - minimum 500 µm²; Neurite Filtering - Best; Neurite sensitivity - 0.4; Neurite Width - 2 μm. Total neurite length (in millimeters) and number of branch points were quantified and normalized to the average value measured during the 6 h’ period prior to sample addition. Total neurite length is the summed length of neurites that extend from cell bodies, and number of branch points is the number of intersections of the neurites in image field.
Size exclusion chromatography (SEC)
Whole TBS extracts (250 μl) or their void volume SEC fractions (500 μl) were injected into either a Superdex 75 (10/30HR) column or a Superdex 200 (10/300GL) column (GE Healthcare) and eluted at a flow rate of 0.8 ml/min with 50 mm ammonium acetate, pH 8.5. The 1 ml fractions were collected; 0.5 μl of this material was used for ELISA, and the other 0.5 μl was lyophilized and used for Western blotting [65]. Samples were electrophoresed on 26-well, 4–12% polyacrylamide Bis-Tris gels using MES running buffer (Invitrogen), and proteins were transferred to 0.2 μm nitrocellulose filters, the filters microwaved, and Aβ detected using a mixture of mAbs 2G3,21F12 (each at 1 μg/ml) and 0.5 μg/ml of mAb 6E10. Membranes were rinsed and incubated for 1 h with fluorescein-conjugated goat anti-rabbit or anti-mouse IgG (1:5,000; Invitrogen), and bands visualized using a LiCor Odyssey Infrared System.

Cerebrospinal fluid sample collection and processing
Samples were collected from the L3/L4 interspace and transferred into nonabsorbing (polypropylene) tubes. CSF samples were mixed by gently inverting three or four times and then centrifuged at 400×g for 10 min. The crystal-clear supernatant was removed to a polypropylene tube and centrifuged at 2,000×g for 10 min, and aliquots of the supernatant were transferred to polypropylene storage tubes and stored at −80 °C.

Cellular Aβ (7PA2 CM) preparations
Secreted human Aβ peptides were collected and prepared from the conditioned media (CM) of a CHO cell line (7PA2) that stably expresses human APP751 containing the V717F AD mutation [52]. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum, 1% penicillin/streptomycin, 2 mM L-glutamine, and 200 mg/ml G418 for selection. Upon reaching ~95% confluency, the cells were washed and cultured overnight (~15 h) in serum-free medium. CM was collected, spun at 1500×g to remove dead cells and debris, and stored at 4 °C. The CM was concentrated 10-fold with a YM-3 Centricon filter [73]. The concentrated CM was pooled and aliquoted to produce a large number of identical medium samples for experiments. These concentrated 7PA2 CM aliquots were stored at −80 °C until use. To prepare the N-terminal extension of AβSs, 7PA2 CM was first incubated with DE23 anion-exchange cellulose to bind and remove the highly charged APPs while leaving the various 4–17 kDa Aβ-immunoreactive products in solution. This APP pre-clearing step generated CM that could then be quantitatively immunodepleted of the NTE species with the pre-β antiseraum. C8, an antiseraum directed to the APP C-terminus, served as a negative control since it did not immunodeplete any of the Aβ-containing species found in 7PA2 CM.

Preparation of synthetic Aβ, including S26C dimers and dityrosine dimers
Synthetic Aβ(1–36), Aβ (1–37), Aβ(1–38), Aβ(1–39), Aβ(1–40), Aβ(1–42), Aβ (1–43), Aβ(1–45) and Aβ(1–46) all were purchased from AnaSpec (Fremont, CA). Synthetic Aβ(1–16) and Aβ (17–42) were purchased from rPeptide (Watkinsville, GA). Monomeric Aβ was prepared as described previously [72]. Aβ S26C-dimers were synthesized and purified using reverse-phase high performance liquid chromatography. Briefly, Aβ(1–40) was dissolved at 2 mg/ml in 50 mM Tris–HCl, pH 8.5, containing 7 M guanidinium HCl and 5 mM ethylenediamine tetraacetic acid, and incubated at room temperature overnight. The sample was then centrifuged at 16,000×g for 30 min and the upper 90% of supernatant applied to a Superdex 75 10/300 size exclusion column (GE Healthcare Biosciences, Pittsburgh, PA, USA), eluted at 0.5 ml/minute with 50 mM ammonium bicarbonate, pH 8.5, and absorbance monitored at 280 nm. Fractions of 0.5 ml were collected. The UV absorbance at 275 nm was determined for the peak fraction and the concentration of Aβ determined using ε275 = 1,361/M/cm [51]. Dityrosine cross-linked Aβ dimer ((Aβ(1–40))2DIY) was prepared as reported previously and SEC-isolated as described above. The UV absorbance at 283 nm of the dimer peak fraction was measured and the concentration of diy dimer determined using ε283 = 6,244/M/cm. (Aβ(1–40)S26C)2 was prepared as described previously and the dimer was SEC-isolated as outlined above. The UV absorbance at 275 nm of the (Aβ(1–40)S26C)2 peak was measured and the concentration of this dimer determined using ε275 = 2,722/M/cm .

Following collection and concentration determination, monomer and dimer peak fractions of the respective oligomer preparations were diluted to 48.5 μM and aliquots (20 μl) were immediately frozen on dry ice and then stored at −80 °C. Once thawed, aliquots were used immediately either for characterization (using analytical SEC and electron microscopy) or as standards in the MSD or Erenna immunoassays.

Preparation of synthetic pre-Aβ and N-terminally extended Aβ peptides
Synthetic preAβ and N-Terminally Extended Aβ preparation were similar to previously described [68]. Five variants of preAβ and NTE-Aβ were produced with extensions of 10, 20, or 30 residues from the APP sequence added to the N-terminus of Aβ1–40. The genes for N-terminally extended variants (by 10, 20, or 30 residues from APP) were produced through a stepwise extension of the synthetic Aβ1–40 by PCR using
oligonucleotides with the desired extensions with *E. coli* preferred codons. Aβ<sub>1-40</sub> and the N-terminally extended variants were expressed in *E. coli* (BL2 DE3 PLYsS Star). The peptides were purified using ion exchange and size exclusion steps. The purity of the peptides was confirmed by SDS PAGE, RP-HPLC and MALDI-TOF mass spectrometry. Purified peptides were stored as lyophilized aliquots.

**Aβ1-x, Aβx-40 and Aβx-42 enzyme-linked immunosorbent assays (ELISA)**

Assays utilized the Meso Scale Discovery (MSD) platform and reagents from Meso Scale (Rockville, MD). MULTI-ARRAY® 96 well small-spot black microplates were coated with 3 μg/ml of monoclonal antibody 266 in tris buffered saline (TBS) and incubated at RT for 18 h. Monoclonal antibody 266 recognizes the mid-region of Aβ, thus enabling detection of both N- and C-terminally heterogeneous Aβ species. Binding sites that were unoccupied were blocked in 150 μl of 5% Blocker A (MSD) in TBS containing 0.05% tween 20 (TBST) and agitated at 400 rpm for 1 h and 22 °C. Plates were washed 3 times with TBST and samples, and standards were applied in duplicate, and agitated at 400 rpm for 2 h and RT. After the capture phase, plates were washed 3 times with TBST and incubated with biotinylated antibody. To allow the detection of Aβ1-x or Aβx-42, we used biotinylated 3D6 (1 μg/ml) or 21F12 (1 μg/ml), respectively. Simultaneously, 1 μg/ml of the reporter reagent (SULFO-TAG Labelled Streptavidin) was added in ELISA diluent and incubated at RT with gentle agitation for 2 h. Finally, plates were washed 3 times with TBST and 2× MSD read buffer (150 μl per well) was applied to allow for electrochemiluminescence detection. A SECTOR imager was used to measure the intensity of emitted light, thus allowing quantitative measurement of analytes present in the samples.

**Statistical analysis**

The LTP and LTD values reported throughout were measured at 60 min after the conditioning stimulus unless stated otherwise. Results were expressed as means ± SEM from at least 4 independent biological samples. Two-tailed Student’s t-test and one-way analysis of variance (ANOVA) were used to determine statistical significance throughout. For live-cell imaging experiments, samples and treatments were coded and tested in a blinded manner. Differences between groups were tested with One-way analysis of variance (ANOVA) with Bonferroni *post-hoc* tests or student’s *t*-tests (*p* < 0.05, **p** < 0.01, and ***p** < 0.001).

**Results**

**Soluble AD brain extracts rich in aqueously-soluble Aβ inhibit hippocampal LTP**

We previously reported that soluble, human brain-derived Aβ oligomers inhibit hippocampal LTP [35, 64]. We first confirmed that some soluble Aβ-rich extracts of neuropathologically validated human (AD) cerebral cortex robustly and consistently inhibit hippocampal LTP while not altering basal synaptic transmission before the high-frequency stimulus (HFS) (control brain that were from age-matched neurologically normal human cortical extracts: 158 ± 6%, *n* = 8 vs. AD brain: 130 ± 4%, *n* = 8; *p* < 0.001) (Fig. 1a). However, cortical extracts from some other AD brains prepared using the identical procedure failed to inhibit LTP (control: 169 ± 12%, *n* = 6, vs. AD: 165 ± 9%, *n* = 7; *p* > 0.05) (Fig. 1b). Several other AD brain extracts also did not inhibit hippocampal LTP (4 out of 25, i.e. 16% of total tested AD brain. Figure 1c, red), while all non-AD brain extract did not impair LTP (Fig. 1c, blue). All clinical and neuropathological data of the AD patients and controls were listed on Additional file 1: Table S1. To verify whether the AD brain extracts that inhibited LTPs were soluble Aβ-dependent, we chose 7 AD brain extract samples that inhibited hippocampal LTP and immunodepleted their soluble Aβ by a high-titer polyclonal antiserum (AW7) to human Aβ (Additional file 1: Figure S1). Consistent with our previous finding [64], the immunodepleted AD brain extracts failed to inhibit LTP (Fig. 1d).

To further explore whether the AD brain extract-mediated impairment of LTP is dependent on the level of soluble Aβ [64], we plotted the mean LTP levels vs. the mean Aβ<sub>x-42</sub> and Aβ<sub>x-40</sub> concentrations determined by specific ELISAs (Fig. 1e, f). The impairment of LTP was weakly correlated with either [Aβ<sub>x-42</sub>] ([R<sup>2</sup> = 0.04, *p* > 0.05]) or [Aβ<sub>x-40</sub>] ([R<sup>2</sup> = 0.16, *p* > 0.05]). These results suggest that although AD brain Aβ levels are significantly higher than control brain levels, LTP impairment does not correlate directly with the total brain tissue Aβ level as detected by ELISA (Fig. 1e, f). Collectively, these results confirm previous findings that Aβ per se, not other components of the AD brain extracts, are responsible for the LTP impairment, but raise the possibility that Aβ conformation or assembly state, not simply the total Aβ monomer levels, may be another factor for its bioactivity.

**Aβ oligomer-rich bioactive AD brain extracts induce neurotoxicity in iPSC-derived human neurons**

To further verify whether bioactive AD brain extracts that inhibit hippocampal LTP can induce other forms of neurotoxicity, we employed a live-cell imaging paradigm using time-lapse video microscopy on an Essen IncuCyte apparatus to monitor the effects of the same AD brain extracts on iPSC-derived, neurogenin-induced human neurons.
neurons [86]. Consistent with the Aβ-impaired synaptic function, a bioactive AD brain extract (Fig. 1a) also induced marked deficits of neurites as regards their length (Fig. 2b: red) and branch point number (Fig. 2c: red), both of which were reduced 50–60% compared to identical treatment with a control brain extract (Fig. 2b, c: black). Applying the Aβ-immunodepleted aliquot from this bioactive AD brain extract, the neurite length and branch point number were normal (Fig 2a; Fig. 2b, c - tan). Interestingly, when we applied a non-bioactive AD brain extract (Fig. 1b) to the iPSC neurons, neurite length and branch points remained unchanged (Fig 2a; Fig. 2b, c - blue), indicating that by both mouse hippocampal slice LTP and this human neuron assay, the inactive extract contains very low or no neurotoxic species. The Aβ-immunodepleted aliquot of this inactive AD sample was likewise inactive, as expected (Fig. 2b, c - light blue). These results suggest that Aβ-rich AD brain extracts interrupt both synaptic function and neurite intactness.

Soluble oligomers but not other Aβ forms inhibit hippocampal LTP
Aβ is pleomorphic and can populate a range of assemblies, with forms ranging from the monomer all the way...
to the aggregates of insoluble ~8 nm fibrils found in amyloid plaques. In the past two decades, most studies have focused on aqueously soluble Aβ assemblies with sizes intermediate between monomer and fibrils [30]. To confirm our previous reports [64, 81], we chose four neuropathologically typical AD brains and two age-matched control brains and prepared a series of Aβ-rich extracts: insoluble amyloid plaque cores and buffer-soluble fractions separated by Superdex 75 size-exclusion chromatography (SEC) that include the void volume (>70 kDa), high molecular weight (HMW, 17~60 kDa), oligomers (6~16 kDa) and ~4 kDa.
monomers. Consistent with earlier findings [64], the plaque core-rich extracts did not alter LTP (140 ± 8%, n = 6 vs. vehicle alone 147 ± 9%, n = 7, p > 0.05 (Fig. 3a), while Aβ oligomers released from the insoluble plaques by formic acid inhibited LTP (116 ± 5%, n = 7). Large soluble assemblies (void volume) from a Superdex 75 SEC column did not significantly alter LTP (145 ± 8%, n = 8 vs. vehicle alone: 158 ± 8%, n = 7, p > 0.05) (Fig. 3b), but when the void volume fraction was incubated at 37 °C for 2 days, the large Aβ assemblies were dissociated into smaller Aβ oligomers that could inhibit hippocampal LTP (122 ± 4%, n = 8). Figure 3c summarizes the effects on LTP of SEC fractions isolated from AD and control brain extracts, confirming that smaller soluble Aβ oligomers confer LTP impairment.

Fig. 3 Soluble Aβ oligomers inhibit hippocampal LTP. (a) Insoluble amyloid plaque cores from AD cortex fail to inhibit the LTP (red), while LTP was inhibited if an equivalent aliquot of the cores was solubilized in 88% formic acid and neutralized with NaOH (blue). (b) The void volume fraction of a Superdex 75 SEC chromatography of an AD cortex TBS extract (red) showed no significant LTP inhibition, but incubating the void volume fraction at 37 °C for 2 days released lower MW soluble Aβ oligomers that significantly impaired LTP (blue). (c) Summary LTP data of the indicated AD brain fractions (n = 6~8). (d) Representative western blot shows different MW SEC fractions of soluble Aβ-rich AD cortical extracts; (e) Oxidized synthetic [Aβ40–526C]2 dimers (blue diamonds) cause significant LTP inhibition but monomeric Aβ1–40 does not (red); (f) Dose-dependent LTP inhibition by oxidized synthetic [Aβ40–526C]2 dimers (red), and dityrosine cross-linked Aβ1–40 dimers (DiY) (blue). *: p < 0.05; **: p < 0.01
To further verify these results, we used two synthetic crosslinked Aβ dimers \([51]\); S26C dimers (Aβ\(_{1-40}\) with a cysteine residue in place of Ser\(_{26}\), allowing formation of disulfide crosslinked dimers) and DiY dimers (wt Aβ\(_{1-40}\) having a tyrosine at position 10, can be crosslinked to a dityrosine-linked dimer by oxidation). To assess the LTP effects of monomers and dimers, we used 100 nM Aβ\(_{1-40}\) and 5 nM S26C\(_2\) dimers. The 100 nM monomers had no effect on LTP (139 ± 4%, \(n = 7\) vs. vehicle: 150 ± 4%, \(n = 7\), \(p > 0.05\)) (Fig. 3e), while 20-fold less concentrated dimers significantly impaired LTP (116 ± 4%, \(n = 7\)). Figure 3f shows a dose-dependent LTP inhibition by S26C\(_2\) dimer; a similar effect can be observed with the DiY dimers.

**Soluble Aβ oligomers from other sources also inhibit hippocampal LTP**

CSF is in direct contact with the extracellular space of the brain, and the principal species of Aβ that can be detected in CSF are aqueously soluble. To test whether the soluble Aβ from human brain plays a role in altering hippocampal LTP, we collected the CSF from the mild AD patients and concentrated them into 50 μl aliquots, then added one to the perfusion buffer (10 ml) of a mouse brain slice. LTP was significantly reduced by the AD CSF samples, while the CSF from age-matched non-AD controls produced no change vs. vehicle (Ctrl: 141 ± 4%, \(n = 6\) vs. AD: 109 ± 6%, \(n = 7\), \(p < 0.001\)) (Fig. 4a). When Aβ removed from the AD CSF by AW7 immunodepletion, hippocampal LTP was restored to the control level (135 ± 6%, \(n = 6\)).

To investigate whether Aβ isolated from APP tg mouse brain has an effect on LTP, we chose hAPP V717F mice generated by Mucke et al. [44], which have elevated levels of Aβ42 and Aβ42/40 ratio and develop Aβ deposits and plaque formation at 8 months of age. The brains of five 7-months-old J20 mice and 5 wild-type littermates were harvested, and Aβ extracts were prepared similarly to the AD brain extracts. The J20 but not the wild-type extracts impaired hippocampal LTP (150 ± 7%, \(n = 5\) vs. 107 ± 3%, \(n = 7\), \(p < 0.001\)), and the LTP inhibition was Aβ-dependent because immunodepleted J20 brain extract had no effect on LTP (146 ± 12%, \(n = 6\)) (Fig. 4b).

Another Aβ source is naturally secreted, soluble amyloid-β oligomers generated in a cell culture model termed 7PA2 cells, which express hAPP with the familial AD “Indiana” mutation (APPV717F). These cells secrete...
Aβ dimers and trimers [52] but have also been shown to secrete some N-terminally extended monomers that extend from aa -31 to aa 40 and 42 (based on Aβ numbering) [77]. In line with other sources of Aβ, the 7PA2 CM (total Aβ 1514 ± 824 pg/ml) inhibited LTP (156 ± 5%, n = 6 vs. 106 ± 4%, n = 7, p < 0.001) (Fig. 4c). Immunodepleting Aβ prevented the inhibition of LTP to control levels (138 ± 7%, n = 7). Lastly, the widely used synthetic Aβ_{1–42} peptide (500 nM) significantly impaired hippocampal LTP (156 ± 5%, n = 6 vs. 111 ± 3%, n = 7, p < 0.001) (Fig. 4d). These results suggest that multiple sources of soluble Aβ, wherever from human or rodent and cell derived or synthetic, can specifically and significantly inhibit hippocampal LTP.

**Certain soluble Aβ fragments inhibit hippocampal LTP**

Amyloidogenic processing of the amyloid precursor protein (APP) by β- and γ-secretases generates several biologically active products, including different Aβ fragments and the APP intracellular domain. It has been found that Aβ_{37}, Aβ_{38}, Aβ_{39}, Aβ_{40}, Aβ_{42}, Aβ_{43} can all be detected in human cerebrospinal fluid [23, 66], while even longer, more hydrophobic Aβ peptides (Aβ_{45}, Aβ_{46}) can be found in cell lysate [53]. To examine the potential effects of these various species, 200 nM concentrations of Aβ_{1–37} to Aβ_{1–46}, were added to the hippocampal slice perfusate for 30 min prior to a HFS that would induce LTP. Aβ_{1–37}, Aβ_{1–38} and Aβ_{1–39} and Aβ_{1–40} peptides had little or no significant effect on LTP. Aβ_{1–42}, Aβ_{1–43}, Aβ_{1–45}, and Aβ_{1–46} each significantly inhibited LTP (Fig. 5a, c). We speculated that Aβ_{1–46} might be more potent than Aβ_{1–42} in inhibiting LTP, so we tried different concentrations of Aβ_{1–46}: (200 nM, 100 nM, and 50 nM), but the degree of LTP impairment did not differ significantly (data not shown).

In addition to variable C-terminally truncated Aβ species, N-terminally truncated Aβs were also found in AD brain [6]. To assess whether the N-terminally truncated Aβs have any effect on the hippocampal LTP, we chose Aβ_{1–16}, and Aβ_{17–42} to test their bioactivity on the brain slices. Consistent with short form of Aβ_{1–37}, the Aβ_{1–16} (200 nM) has no significant effect on the LTP (146 ± 5%, n = 7 vs. 156 ± 6%, n = 7, p > 0.05, Fig. 5b, c). Interestingly, the Aβ_{17–42} (200 nM) has a partial effect on the LTP (127 ± 5%, n = 7 vs. 156 ± 6%, n = 7, p < 0.01, Fig. 5b, c), this result further suggests that the hydrophobic C-terminal of Aβ_{1–42} may initiate the Aβ aggregation to form the toxic Aβ species.

We previously reported the existence of APP proteolytic fragments released by certain cultured cells that

---

**Fig. 5** Soluble Aβ peptides with longer C-termini confer greater synaptic toxicity. (a) The short Aβ_{1–37} synthetic peptide did not impair hippocampal LTP at concentrations of 200 nM (red, n = 7, p > 0.05), while the same dose of the longer Aβ_{1–42} peptide showed significant inhibition (blue, n = 6, p < 0.001); (b) N-terminally truncated synthetic Aβ_{1–16} and Aβ_{17–42} effect on the hippocampal LTP. (c) Summary data of LTP effects of Aβ peptides of increasing lengths at 200 nM concentrations. (d) The whole 7PA2 CM as well as immunoprecipitated NTE-Aβs (black open circles, n = 7, p < 0.001) and the CM remaining CM after depletion of APPs by DE23 resin (red circles, n = 7, p < 0.001) all inhibit LTP, while the isolated APPs alone (blue diamonds, n = 7, p > 0.05) does not; (e) Treatment of slices with synthetic pre-Aβ (~30 to ~1) does not facilitate synthetic Aβ_{1–40} to induce synaptotoxicity, that is, to say, a synthetic APP-34 to ~1 fragment added to an Aβ_{1–40} peptide does not inhibit LTP (n = 6, p > 0.05); (f) Summary data of synthetic peptides containing or not various lengths (~10 – 20, ~30) of APP prior to the Aβ_{1–40} Asp1 start site (called "preAβ") and N-terminal extension on Aβ_{1–40} do not inhibit LTP. (n = 6–8). *, p < 0.05; **, p < 0.01
contain the entire Aβ region plus a variable-length N-terminal extension (NTE), including a species beginning at least 34 residues N-terminal to the Asp1 start site of Aβ. We found that such NTE-Aβ monomers are secreted along with Aβ monomers and dimers by CHO cells stably expressing the FAD APP V717F mutation (called 7PA2 cells), and they contribute to the impairment of LTP by the 7PA2 CM [77]. Here, we showed that whole 7PA2 CM (0.5x, fresh made 7PA2 CM or called pre-7PA2; the total Aβs concentration by ELISA is 757 pg/ml) and the CM after depleting it of secreted APPs-α with DE23 resin (called post-7PA2) blocked LTP, while the APPs fraction itself did not alter LTP (Fig. 5d).

In order to characterize certain pre-Aβ (the APP fragments before the Aβ starting point of APPs) fragments of APP (−30 to −1, −20 to −10, −10 to −10) and also Aβ species having such N-terminal extensions (−30 to +40, and −10 to +40), we applied these peptides at 1 μM concentrations; the preAβs and short form NTEs did not inhibit LTP (Fig. 5e, f). Then, we combined the preAβ20 to −1 peptide with the Aβ1−40 peptide; the mixed peptides did not cause Aβ1−40 to induce synaptic dysfunction (Fig. 5e). These results suggest that pre-Aβ, Aβ1−16, Aβ1−39, and NTE (−30 to +40), all of which are relatively more hydrophilic than the synaptotoxic Aβ1−42, are non-synaptotoxic, whereas the longer forms (Aβ1−42 to Aβ1−46) that are more hydrophobic and more prone to aggregate were toxic species.

Antibodies to the N-terminus of Aβ prevent the LTP inhibition
Active immunization with synthetic Aβ peptides or passive infusions of humanized anti-Aβ monoclonal antibodies has been widely investigated as an immunotherapeutic approach to treat and prevent clinical AD. To examine this approach in tightly-controlled, reductionist experiments, we conducted a series of studies of hippocampal LTP and LTD in the absence or presence of antibodies raised to various human APP sequences within and flanking the Aβ region. The antibodies and their epitopes were 3D6 (requires a free Asp1 at the Aβ N-terminus), 82E1 (recognizes a free Asp1 at the Aβ N-terminus), 6E10 (to aa 3–8), 266 (to aa 13–28), 4G8 (to aa 17–24), 2G3 (requires a free Gly40 at the end of aa 33–40), 21F12 (requires a free Ile42 at the end of aa 33–42) and polyclonal antibody R1282 (principally recognizes epitopes in the N-terminal third of Aβ). To test the effects of these antibodies in rescuing Aβ-impaired LTP, we first tested each antibody (at 1–3 μg/ml) itself whether has any effect on the hippocampal LTP (Additional file 1: Figure S2), then added each antibody to an AD brain extract previously shown to inhibit LTP and incubated with mixing for 30 min before adding the mixture to the slice perfusion buffer. The N-terminal antibody 3D6 but not the C-terminal antibodies 2G3 and 21F12 fully prevented LTP impairment by the soluble Aβ oligomer-rich AD extract (Fig. 6a, b). These results further supported that the N-terminally, not those C-terminally targeted antibodies of Aβ could neutralize Aβ-mediated synaptotoxicity and reduce the pathology of AD model mice [64, 83].

Another feature of synaptic plasticity is represented by long-term depression (LTD), an electrophysiological response known to correlates with dendritic spine shrinkage and synapse collapse [4, 78]. It has become widely used to assess Aβ-induced synaptic dysfunction after we first demonstrated that soluble Aβ oligomers of several sources could facilitate a persistent LTD upon a weak low-frequency (1 cps × 300 s) stimulation that usually fails to induce LTD [10, 16, 34, 38, 50, 56]. Again, two Asp1 N-terminus-specific antibodies, 3D6 and 82E1, but not the C-terminal antibodies 2G3 and 21F12, prevented the Aβ-facilitated LTD (Fig. 6c, d). A broad N-terminal region antibody, 6E10, and a mid-region antibody, 4G8, only partially prevented the Aβ-facilitated LTD. These results further support that the N-terminus of Aβ1−42 plays a crucial role in triggering synaptic dysfunction.

Discussion
Here, we have performed a systematic comparative analysis of numerous features of the well-known inhibition of hippocampal synaptic plasticity by soluble oligomers of human Aβ. Our results complement and extend previous studies from our and other laboratories that found that soluble Aβ oligomers inhibit hippocampal LTP and induce synapse and neurite loss, including by oligomers isolated directly from AD cortex. We show here that Aβ inhibition of LTP is not conferred by monomers but rather by soluble oligomer-rich preparations. We also found that APP proteolytic fragments just prior to the Aβ N-terminus, the short Aβ peptides Aβ1−16, through Aβ1−16 and the N-terminally extended peptide −30 to Aβ40 (APP641−711 of APP770) all failed to significantly inhibit LTP, while the longer, more hydrophobic peptides Aβ1−42 through Aβ1−46 were synaptotoxic. Two different N-terminal antibodies recognizing the free Asp1, 3D6 and 82E1, but not two C-terminal antibodies, could prevent Aβ oligomer impairment of LTP.

Cerebral Aβ accumulation and aggregation are early pathological events in AD, starting some 2 to 3 decades or more before the onset of readily detectable clinical symptoms [5, 18, 19, 67]. Although insoluble, fibrillar aggregates of Aβ constitute the neuropathological hallmark of AD, the number of plaques and the levels of insoluble Aβ correlate weakly with the local extent of synaptic and neuronal loss and thus with cognitive impairment in humans [45, 47]. On the other hand, the levels of soluble assemblies (oligomers) of Aβ appear to correlate better with disease progression in both rodent models and AD subjects [8, 32, 39, 64]. In AD model
mice, spatial learning and memory have been shown to be impaired in nearly all models of Aβ overproduction by transgenic APP expression, and the onset of the cognitive decline occurred close to that of brain amyloid deposition [76]. Despite the genetic evidence suggesting a pivotal role for Aβ, considerable controversy still exists about its precise pathogenic role in AD [46]. This may be due to a lack of reliable approaches for the early AD diagnosis. For example, a sensitive method to detect the Aβ oligomers and its conformations can clarify this controversy, as some Aβ oligomer-detecting techniques (such as sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE)) may be relatively insensitive or even lead to artifacts [75]. The fact that brain Aβ levels measured by largely monomer-specific ELISAs did not correlate closely with degree of synaptotoxicity is not surprising; in contrast, special immunosays that selectively detect soluble Aβ oligomers can readily distinguish extracts of AD vs. age-matched normal brain [14, 59, 74, 82].

The amyloid plaques consist of different variants of the Aβ peptide, with the most abundant being Aβ1–40 and Aβ1–42. AD brain specimen analyses have revealed numerous N-terminal or C-terminal truncated or modified Aβ species in addition to the full-length Aβ1–40 and Aβ1–42 [17, 37, 54, 55]. The sequential hydrolysis of APP by γ-secretase in AD generates a step-wise series of Aβ peptides terminating in residues 49, 48, 46, 45, 43, 42, 40, 39, 38 and 37 [53, 69]. Here we found that synthetic Aβ fragments longer than 1–40, including Aβ1–42, Aβ1–43, Aβ1–45 and Aβ1–46, confer significant impairment of LTP, while the shorter forms of Aβ1–16, Aβ1–37, Aβ1–38, Aβ1–39 and Aβ1–40 have little effect on synaptic function. It is generally accepted that Aβ1–42 plays a more pivotal role in AD pathogenesis than Aβ1–40 because of its much higher aggregation propensity and thus neurotoxicity [58]. It has been considered that the C-terminal hydrophobic residues in Aβ42 are a driving force for protein misfolding and self-assembly, leading to stabilization of neurotoxic low-order oligomers (dimers and larger)

Fig. 6 N-terminal antibodies prevent interruption of hippocampal synaptic plasticity by soluble Aβ-rich brain extract. (a) Asp1 N-terminus specific Aβ antibody, 3D6 (red circles), not the C-terminal-specific antibodies 2G3 + 21F12 (blue diamonds) prevent the AD brain TBS extract (purple traces) from inhibiting LTP. (b) Summary data of antibodies to different Aβ epitopes as to their effect on AD brain TBS extract impairment of LTP (N ≥ 6 recordings for each antibody). (c) N-terminal antibody 3D6 (red circles), not the C-terminal target antibodies, 2G3 + 21F12 (blue diamond) prevent the AD brain extract (purple traces) from facilitating LTD. (d) Summary data of antibodies to different Aβ epitopes as to their effect on the AD brain extract’s facilitation of LTD (N > 5 recordings for each antibody). *, p < 0.05; **, p < 0.01.
neutralization. Therefore, C-terminal anti-
is exposed and is considered an avenue neurotoxic
is then inaccessible to antibodies, while the N-terminus
which forms part of the core structure of the aggregates
is likely have a greater propensity to aggregate into oligomers and bind
to the cell membrane because of their longer hydropho-ic C-termini residues. And the shorter forms have been
shown in some studies to have anti-amyloidogenic prop-
erties [33].

In addition to the above C-terminally heterogeneous
Aβ species, N-terminally extended Aβ (NTE-Aβ) mono-
mers with up to 9 residue extensions also have been
detected in human plasma [24]. We previously reported
that the CM of 7PA2 cells (CHO cells expressing the
hAPP V717F FAD mutation) that is rich in NTE-Aβ var-
iants as well as Aβ monomers and dimers could block
hippocampal LTD. Immunodepletion of the NTE mono-
ners with a pre-Aβ region polyclonal antibody pre-
vented the 7PA2 CM-mediated LTD impairment, and
removing all Aβ species with a pan-Aβ antiserum R1282
prevented the LTP impairment, suggesting that the
monomeric N-terminally extended APP fragments con-
taining the entire Aβ region can impair LTD [77].

To further compare the effects of N-termini vs.
C-termini of Aβ on synaptic plasticity, we used several
epitope-specific antibodies. We found that antibodies to
the N-terminus starting with a free Asp1 (3D6 and
82E1) could fully rescue the impaired LTD and enhanced
LTD caused by AD-TBS extracts, while two C-terminal
antibodies (2G3 and 21F12) had no effect. The mid-region targeted antibodies (6E10, 266 and 4G8) had
minor effects that did not reach significance. These re-
results confirm previous reports including ours that anti-
bodye which target the N-terminus, but not those
targeting the C-terminus, can neutralize Aβ-mediated
synaptotoxicity and reduce Aβ plaque load [3, 64, 83],
thus leading to most anti-Aβ antibodies in clinical trials
targeting the N-terminus or mid-region. However, sev-
eral earlier studies using C-terminal antibodies, deglyco-
sylated antibodies (D-2H6) and naturally occurring
auto-antibodies against Aβ (NAbs–Aβ), were reported to
significantly reduce Aβ burden and reverse cognitive
deficits in AD mouse model [11, 25, 79]. The differential
effects of N-terminal vs C-terminal anti-Aβ antibodies
may be due to experimental paradigm differences in AD
mouse models, such as dosing, administration mode or
ages of treatment. The hydrophobic C-terminus of Aβ12
which forms part of the core structure of the aggregates
is then inaccessible to antibodies, while the N-terminus
is exposed and is considered an avenue neurotoxic
neutralization [48, 83, 85]. Therefore, C-terminal anti-
bodies may be more active in the preclinical stages of
AD, by binding to low aggregated (more soluble) Aβ
oligomers, whereas N-terminal antibodies may better ac-
cess highly aggregated Aβ oligomers and fibrils (associ-
ated with a later disease state).

Although others find the seeding activity of AD
brain-derived Aβ to be at least 100 times more potent
than that of Aβ from CSF or synthetic Aβ in young APP
transgenic mice, we find that all sources inhibit hippo-
campal LTD in brain slices [12, 40]. Together with the
fact that C-terminal Aβ antibodies did not rescue the
Aβ-impaired synaptic function in vitro, while C-terminal
antibodies could improve cognitive function in APP Tg
mice [11, 25, 79]. Such discrepancies may be due to the
experimental paradigm. Our experimental conditions in
slice LTD studies are reductionist compared to the com-
plexities of Aβ production, aggregation and clearance
that are dynamic in vivo, as well as effects of the
blood-brain barrier and Aβ-degrading enzymes which
are not considered in hippocampal slices. These factors
will need to be addressed in further in vivo LTD studies
to verify our conclusions. Another possibility is the dif-
ferent readout: the synaptic plasticity in present study
vs. the behavior or cerebral β-amyloidosis in others.
Additional specific functional biomarker (i.e. integrative
EEG, event-related potentials and oscillations) that cor-
related with cognition or β-amyloidosis will clarify the
present conclusion.

Unfortunately, several antibodies targeting Aβ have
failed in clinical trials, including bapineuzumab [57], a
humanized monoclonal antibody directed against the
N-terminus of Aβ that recognizes the amyloid beta 1–5
region [41], similar to murine monoclonal antibody 3D6.
The reasons are likely attributable to its very low dosing
in the trials due to the first appearance in AD immuno-
therapy of amyloid-related imaging abnormality-edema
(ARIA-E). The relatively late symptomatic stage (mild-
moderate AD) of subjects in this and other antibody tri-
als could also contribute to a failure to significantly slow
cognitive decline. More recent trials that began treating
at early or very early symptomatic stages of AD and used
substantial doses of N-terminally-directed antibodies ap-
pear to clear amyloid plaques and lead to some apparent
slowing of cognitive decline [61, 63]. Our results indi-
cated that preventing soluble Aβ oligomer formation
and targeting their N-terminal residues with antibodies
could be an attractive combined therapeutic approach.

Conclusions
In this study, we have performed a systematic compara-
tive analysis of numerous features of the well-known inhibi-
tion of hippocampal synaptic plasticity
by soluble oligomers of human Aβ. Our results provide
evidence that preventing soluble Aβ oligomer formation
and targeting their N-terminal residues with antibodies
could be an attractive combined therapeutic approach.
Additional file

**Additional file 1: Table S1.** Demographic and pathological data on brain samples. Figure S1. Characterization of AD brain extracts used for LTP experiments. (a) Half milliliter aliquots of mock immunodepleted (AD) and AW7 immunodepleted (ID-AD) extracts were analyzed by IP/WB. AW7 was used for IP and a combination of 2G3 and 2FIT was used for WB. To enable comparison 2 and 5 ng of Aβ1–42 peptide was also electrophoresed on the gel. IP/WB analysis allows the capture of Aβ structures under native conditions and their detection following denaturing SDS-PAGE. (b) The same samples were also analyzed by an MSD-based Aβx-42 immunoassay. Since GuHCl effectively disaggregates high molecular weight Aβ species, samples were analyzed with and without incubation in denaturant. Analysis of samples in the absence of GuHCl allows the measurement of native Aβ monomer, whereas, analysis of samples treated with GuHCl allows detection of disassembled aggregates. The AD extracts contained much larger amounts of aggregates than monomer, and both monomer and aggregates were effectively removed by AW7 immunodepletion. The experiments shown are typical of at least 3 separate experiments. Figure S2. Bath application of anti-Aβ antibodies had no significant effect on hippocampal LTP. Each data in this graph was average of at least 6 recordings. (DOCX 466 kb)

Acknowledgments

We thank Drs. Dominic Walsh and Zemin Wang for their expert advice. We thank Nina Shepardson and Molly Rajombsbath for preparing 7PA2 CM and CHO- CM, Wei Hong and Ting Yang for preparing AD and control brain TBS extracts, Marty Fernandez for preparing Aβ1-40, and Aβ1-42 and Tieman O’Malley for preparing S26C dimers and DIY dimers. Supported by Alzheimer’s Association NIROG-12-242825 (SL) and NIH grant AG006173 (D.L.S).

Authors’ contributions

SL carried out electrophysiological experiments and analyzed the data. MJ carried out living-cell imaging study. LL and BLO prepared the Aβ42 extracts, Marty Fernandez for preparing S26C dimers and DIY dimers. Supported by Alzheimer’s Association NIROG-12-242825 (SL) and NIH grant AG006173 (D.L.S).

Competing interests

DJS is a director of and consultant to Prothera Biosciences. The other authors declare that they have no conflicts of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 29 October 2018 Accepted: 29 October 2018

Published online: 08 November 2018

References

1. Ahmed M, Davis J, Aucocin D, Sato T, Khuya S, Aimoto S et al (2010) Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 17:561–567
2. Arendt T (2009) Synaptic degeneration in Alzheimer’s disease. Acta Neuropathol 118:167–179
3. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D et al (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A 100:2023–2028
4. Bartsch N, Gardner GA, Reece JM, Jeromin A, Dudek SM (2008) Synapse elimination accompanies functional plasticity in hippocampal neurons. Proc Natl Acad Sci U S A 105:3123–3127
5. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804
6. Bayer TA, Wirths O (2014) Focusing the amyloid cascade hypothesis on N-truncated Aβ peptides as drug targets against Alzheimer’s disease. Acta Neuropathol 127:787–801
7. Bilusuova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C et al (2016) Synaptic Amyloid-B β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. Am J Pathol 186:185–198
8. Brody DL, Jiang H, Wildburger N, Espana TJ (2017) Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease. Alzheimers Res Ther 9(1):62. https://doi.org/10.1186/s13195-017-0293-3
9. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM et al (2011) Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 25:775–784
10. Chen X, Lin R, Chang L, Xu S, Wei X, Zhang J et al (2013) Enhancement of long-term depression by soluble Aβ protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3. Neuroscience 253:435–443
11. Dodel R, Balakrishnan K, Keyhani K, Deustner O, Neff F, Andrei-Selmer LC et al (2011) Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer’s disease. J Neurosci 31:5847–5854
12. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolkburg H et al (2010) Peripherally applied Abeta-containing inoculates induces cerebral beta-amyloidosis. Science 330:980–982
13. Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, Schuler DR et al (2014) Genetic modulation of soluble Aβ resuces cognitive and synaptic impairment in a mouse model of Alzheimer’s disease. J Neurosci 34:7871–7885
14. Henkoviitas AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. (2013) A Luminex assay detects amyloid β-oligomers in Alzheimer’s disease cerebrospinal fluid. PLoS one 2013 Jul 28;8(7):e67898
15. Hisa AY, Miyashita F, Concomole L, Yu GQ, Tatsuno G, Hu K et al (1999) Plaque-independent disruption of neuronal circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci U S A 96:3228–3233
16. Hu NW, Nicoll AJ, Zhang D, Mably AJ, O’Malley T, Purro SA et al (2014) miGUS receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nat Commun 5:3374
17. Iwasubo T, Ōdaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of Aβ 42(43) and A 340 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 13:45–53
18. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9(11):119–128
19. Jansen WJ, Ossenkoppele R, Knol DL, Tiijms BM, Scheltens P et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313:1924–1938
20. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD et al (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408:979–982
21. Jin M, O’Nuallain B, Hong W, Boyd J, Lagomarsino VN, O’Malley TT, et al. (2018) An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease. Nat Commun. 2018 Jul 11;9(1):2676
22. Kakuda N, Miyasaki T, Iwasaki N, Nirasawa T, Wada-Kakuda S, Takahashi-Fujigasaki J et al (2017) Distinct deposition of amyloid-β species in brains with Alzheimer’s disease pathology visualized with MALDI imaging mass spectrometry. Acta Neuropathol Commun 5(1):73. https://doi.org/10.1186/s40478-017-0477-x
23. Kakuda N, Shoji M, Arai H, Furukawa K, Kuechich K, Akazawa K et al (2012) Altered γ-secretase activity in mild cognitive impairment and Alzheimer’s disease. EMBO Mol. Med. 4:344–352
24. Kaneko N, Yamamoto R, Sato TA, Tanaka K (2014) Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Jpn J Pharmacol. 122(6):1179–1186
25. Karloski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE et al (2008) Deglycosylated anti-Aβ antibodies dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol 3:187–197
26. Kazma A, Penke B, Frank Z, Bozs Z, Szegedi V, Hunya A, et al. (2017) Studies for Improving a Rat Model of Alzheimer’s Disease: ivy Administration of Well-Characterized β-Amyloid 1-42 Oligomers Induce Dysfunction in Spatial Memory. Molecules. 22(11): pii: E2007
27. Klyubin I, Betts V, Weixel AT, Blennew K, Zetterberg H, Wallin A et al (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28:4231–4237
28. Klyubin I, Walsh DM, Lemene CA, Cullen WK, Shankar GM, Betts V et al (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556–561
29. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6446–6453
30. Lannfelt L, Möller C, Basun H, Oltswald G, Sehlin D, Sattin A et al (2014) Perspectives on future Alzheimer therapies: amyloid-β prototitlons - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther 6(2):16. https://doi.org/10.1186/1750-939x-6-16
31. Larson J, Lynch G, Games D, Seubert P (1999) Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res 840:23–35
32. Lésné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A et al (2006) A specific amyloid-β proteinase-1 assembly in the brain impairs memory. Nature 440:352–357
33. Levit et Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE (2006) Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Investig 116(1):193–201
34. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62:786–801
35. Li S, Jin M, Köglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extracellular Na+/K-containing NMDA receptors. J Neurosci 31:6637–6638
36. Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis—lessons from amyloid precursor protein processing. J Neurochem 117:779–796
37. Lyons B, Friedrich M, Rafty R, Truscott R (2016) Amyloid Plaque in the Human Brain Can Decompose from Ab(1-40/1-42) by Spontaneous Nonenzymatic Processes. Anal Chem 88(5):2675–2684
38. Ma T, Du X, Pick JE, Gai X, Brownlee M, Klann E (2012) Glutagon-like peptide-1 cleavage product GLP-1(9-36)amide rescues synaptic plasticity and memory deficits in Alzheimer’s disease model mice. J Neurosci 32:13701–13708
39. McDonald JM, Savva GM, Brayne C, Welzé AT, Forster G, Shankar GM et al (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133(Pt 5):1328–1341
40. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Horikoshi Y et al (2005) Longer forms of amyloid beta protein: implications for Alzheimer’s disease-associated amyloid beta-peptide. FEBS J 276:1266–1276
41. Podlisny MB, O’Malley TT, Oktaviani NA, Zhang D, Lomakin A, O’Nuallain B, Linse S et al (2012) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:539–543
42. Q1-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Horiuchi N, Horikoshi Y et al (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurochem 25:436–445
43. Rolheiser HJ, Madsen MM, Dicker CJ, Madsen MH, Madsen EJ (2012) Amyloid beta and other peptides in the Plasma –Secretase Modulator, BMS-932481, Modulates Aβ deposition in an Alzheimer disease mouse model. J Neurosci 32:6510–6520
44. Silverman JH, Chiao P, Bussile T, Weinreb PH, Williams L, Maier M et al (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537:56–59
45. Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM (2011) Isolation and structural diversity and Alzheimer’s disease pathogenesis. Acta Neuropathol 129:183–191
46. Steinberg Z, Brashear A, Selkoe DJ (2018) Light at the end of the amyloid tunnel. Biochemistry, 2018 1 Oct 1. doi: https://doi.org/10.1021/acs.biochem.8b00985
47. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) A βSecretase inhibition mechanism for amyloid β aggregation by catechol-type flavonoids targeting the Λ5 residues. J Biol Chem 289:789–791
48. Soares HD, Gasior M, Toyin JH, Wang JS, Hong Q, Berisha F et al (2016) The γ-secretase Reporter, BMS-932481, Modulates AB Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers. J Pharmacol Exp Ther 358:138–150
49. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292
50. Szczepankiewicz O, Linse B, Meisel G, Thulin E, Frigge B, Bravo LA, Fréger F et al (2015) N-Terminal Extensions Retard AB42 Fibril Formation but Allow Cross-Seeding and Coaggregation with AB42. J Am Chem Soc 137:14673–14685
51. Takami M, Nagashima Y, Sano Y, Itohara S, Morishima-Kawashima M, Funamoto S et al (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29:13042–13052
52. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Arnal Y, Wolfe MS et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:539–543
53. Walsh DM, Thulin E, Minoque AM, Gustavsson N, Penge E, Teplov DB et al (2009) A facile method for expression and purification of the Alzheimer’s disease-associated amyloid beta-peptide. FEBS J 276:1266–1281
73. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O et al (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrilligenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 25:2455–2462.

74. Wang-Dietrich L, Funke SA, Külbach K, Wang K, Besmehn A, Willbold S et al (2013) The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer’s disease. J Alzheimers Dis 34:985–994.

75. Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, Johanssen T et al (2013) Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples. Acta Neuropathol 125:549–564.

76. Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ (2014) Using mice to model Alzheimer’s dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 5:88. https://doi.org/10.3389/fgene.2014.00088.

77. Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S et al (2014) Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry 53:3908–3921.

78. Wiegert JS, Oertner TG (2013) Long-term depression triggers the selective elimination of weakly integrated synapses. Proc Natl Acad Sci U S A 110(47):E4510–E4519.

79. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J et al (2006) Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26:5340–5346.

80. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398:513–517.

81. Yang T, Li S, Xu H, Walsh DM, Selkoe DJ (2017) Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. J Neurosci 37:152–163.

82. Yang T, O’Malley TT, Kamnet C, Jeremic J, Zieske JR, Zetterberg H et al (2015) A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimers Res Ther 7(1):14.

83. Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P et al (2012) Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci 32:2696–2702.

84. Zeng H, Guo M, Martini-Taylor K, Wang X, Zhang Z, Park JW et al (2010) Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS One 5(7):e11853. Epub 2010/08/06.

85. Zhang Y, Chen X, Liu J, Zhang Y (2015) The protective effects and underlying mechanism of an anti-oligomeric Aβ42 single-chain variable fragment antibody. Neuropharmacology 99:387–395.

86. Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S et al (2013) Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78:785–798.